MSLN and cancer: This is clinically relevant from an immunotherapy viewpoint, since Stronen and colleagues recently showed that HLA-matched donor-derived TCRs, that recognize private mutated cancer epitopes (neoepitopes) from patients with cancer, can be transduced into patient-derived T cells for adoptive therapy [22].: anti-mesothelin - reactive T-cells could potentially expanded from the precursor T-cell pool from healthy donors.